Epithelial-mesenchymal Transition Transcription Factors and MiRNAs: "Plastic Surgeons" of Breast Cancer
Overview
Affiliations
Growing evidence suggests that breast cancer cell plasticity arises due to a partial reactivation of epithelial-mesenchymal transition (EMT) programs in order to give cells pluripotency, leading to a stemness-like phenotype. A complete EMT would be a dead end program that would render cells unable to fully metastasize to distant organs. Evoking the EMT-mesenchymal-to-epithelial transition (MET) cascade promotes successful colonization of distal target tissues. It is unlikely that direct reprogramming or trans-differentiation without passing through a pluripotent stage would be the preferred mechanism during tumor progression. This review focuses on key EMT transcriptional regulators, EMT-transcription factors involved in EMT (TFs) and the miRNA pathway, which are deregulated in breast cancer, and discusses their implications in cancer cell plasticity. Cross-regulation between EMT-TFs and miRNAs, where miRNAs act as co-repressors or co-activators, appears to be a pivotal mechanism for breast cancer cells to acquire a stem cell-like state, which is implicated both in breast metastases and tumor recurrence. As a master regulator of miRNA biogenesis, the ribonuclease type III endonuclease Dicer plays a central role in EMT-TFs/miRNAs regulating networks. All these EMT-MET key regulators represent valuable new prognostic and predictive markers for breast cancer as well as promising new targets for drug-resistant breast cancers.
Targeted therapy approaches for epithelial-mesenchymal transition in triple negative breast cancer.
Haque M, Shyanti R, Mishra M Front Oncol. 2024; 14:1431418.
PMID: 39450256 PMC: 11499239. DOI: 10.3389/fonc.2024.1431418.
Navigating the therapeutic landscape for breast cancer: targeting breast cancer stem cells.
Dey S, Dinakar Y, R S, Jain V, Jain R Naunyn Schmiedebergs Arch Pharmacol. 2024; .
PMID: 39441235 DOI: 10.1007/s00210-024-03542-5.
Cancer metastasis under the magnifying glass of epigenetics and epitranscriptomics.
Janin M, Davalos V, Esteller M Cancer Metastasis Rev. 2023; 42(4):1071-1112.
PMID: 37369946 PMC: 10713773. DOI: 10.1007/s10555-023-10120-3.
Fridrichova I, Kalinkova L, Ciernikova S Int J Mol Sci. 2022; 23(20).
PMID: 36292996 PMC: 9603393. DOI: 10.3390/ijms232012141.
MicroRNA expression profiling of endocrine sensitive and resistant breast cancer cell lines.
Khajah M, Al-Ateyah A, Luqmani Y Biochem Biophys Rep. 2022; 31:101316.
PMID: 35879960 PMC: 9307586. DOI: 10.1016/j.bbrep.2022.101316.